Neurological medications treat conditions ranging from epilepsy and Parkinson’s disease to migraines, multiple sclerosis, and Alzheimer’s, yet they share a challenge that drugs targeting the heart or liver rarely face: getting past the blood-brain barrier. This biological filter protects the brain from toxins but also blocks most therapeutic molecules, which is why the history of neuropharmacology is largely a story of clever workarounds. The field has expanded dramatically from the first modern psychiatric drugs discovered by chance in the mid-twentieth century, and several emerging technologies are poised to reshape it again.
Why the Blood-Brain Barrier Makes Brain Drugs Uniquely Difficult
The blood-brain barrier is a tightly sealed layer of cells lining the brain’s blood vessels. Unlike capillaries elsewhere in the body, these vessels have almost no gaps between cells, so molecules that would easily reach the liver or kidneys get turned away at the brain’s doorstep. Only small, fat-soluble molecules tend to cross on their own. That limitation shapes every neurological drug on the market: if a compound cannot slip through or be ferried across, it simply will not work.
Researchers have developed several strategies to get around this problem. Some are invasive, like injecting drugs directly into the cerebrospinal fluid or into the brain itself. Others are subtler: hijacking the barrier’s own transport proteins or receptors to smuggle drugs across, a process called receptor-mediated transcytosis. These less invasive approaches carry their own trade-off, since the same transporters exist in other tissues, so off-target effects remain a concern.1PubMed Central. Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease Focused ultrasound paired with tiny microbubbles offers a newer physical approach: the ultrasound vibrates the microbubbles near brain blood vessels, temporarily loosening the barrier so that drugs can slip through before it seals again.2Advanced Drug Delivery Reviews. Ultrasound-mediated blood–brain barrier opening: An effective drug delivery system for theranostics of brain diseases Animal studies have shown that drug-carrying microbubbles combined with focused ultrasound can deliver a chemotherapy agent directly to brain tumor sites by disrupting the barrier and releasing the drug simultaneously at the target.3PubMed. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment
Seizure Medications and How They Calm Overactive Circuits
Epilepsy drugs (often called antiseizure or antiepileptic medications) are among the oldest neurological medications still in wide use. They work by quieting the electrical storms that cause seizures. Some do this by enhancing the brain’s main inhibitory signal, a neurotransmitter called GABA that essentially tells neurons to slow down. Others block sodium or calcium channels, the tiny gates that let charged particles rush into neurons and trigger firing. Older drugs like phenytoin and carbamazepine lean heavily on sodium-channel blockade, while benzodiazepines and phenobarbital boost GABA signaling.4British Journal of Anaesthesia. Differential interaction of anaesthetics and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABAA receptors Newer agents like levetiracetam and lacosamide use different mechanisms, giving doctors more options when a first drug does not control seizures well enough.
One underappreciated area in epilepsy treatment is neurosteroids, naturally occurring molecules in the brain that modulate GABA receptors. Because they enhance a form of inhibition that broadly dampens network excitability, synthetic versions of neurosteroids are being developed for epilepsy, status epilepticus (prolonged seizures that are a medical emergency), and even traumatic brain injury.5PubMed Central. Clinical Potential of Neurosteroids for CNS Disorders The appeal is that they work through a mechanism the brain already uses, which in theory could mean fewer side effects than drugs that force a receptor into an unnatural state.
Parkinson’s Disease and the Limits of Levodopa
Levodopa has been the cornerstone of Parkinson’s treatment since the 1960s. The brain converts it into dopamine, the neurotransmitter that Parkinson’s patients progressively lose as their dopamine-producing neurons die. In the first few years, levodopa can dramatically improve movement, stiffness, and tremor. But the drug’s effectiveness changes with time. After roughly five years, most patients develop complications: periods where the drug stops working before the next dose kicks in (“wearing off”), involuntary writhing movements called dyskinesias, or outright loss of benefit.6PubMed. Problems with long-term levodopa therapy for Parkinson’s disease
These complications are frustrating to manage. Part of the problem is that levodopa’s absorption from the gut is erratic and influenced by meals, so blood levels swing unpredictably instead of staying smooth. Doctors often add other drugs to extend levodopa’s effect: COMT inhibitors slow its breakdown, dopamine agonists stimulate dopamine receptors directly, and MAO-B inhibitors prevent dopamine from being cleared too quickly. None of these fully solve the problem. The deeper issue is that as neurons continue to die, the brain has fewer cells to convert levodopa into dopamine and to store and release it in a controlled way.
Research into neuroinflammation has added a new dimension to Parkinson’s thinking. Microglia, the brain’s resident immune cells, appear to become chronically activated in Parkinson’s patients and drive a cycle of inflammation that accelerates neuron loss.7PubMed Central. Pharmacological Targeting of Microglial Activation: New Therapeutic Approach Targeting microglia with drugs that tamp down this inflammatory response is a promising strategy, though still largely experimental.8PubMed Central. Microglia Specific Drug Targeting Using Natural Products for the Regulation of Redox Imbalance in Neurodegeneration
Multiple Sclerosis and B-Cell Therapies
Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the protective coating around nerve fibers. For decades, MS treatments focused on broadly suppressing the immune system or modifying its behavior with interferons and other agents. That changed significantly when clinical trials showed that depleting a specific type of immune cell, B cells, could dramatically reduce the inflammatory flare-ups that characterize relapsing MS. Ocrelizumab, a monoclonal antibody that targets the CD20 protein on B cells, was approved in 2017 after trials demonstrated large reductions in inflammatory disease activity in relapsing MS and slowed disability progression even in primary progressive MS, a form that had almost no effective treatments before.9PubMed Central. B-Cell Therapies in Multiple Sclerosis
The success of B-cell depletion was something of a surprise. MS had long been viewed as primarily a T-cell-driven disease, but the clinical results put B cells at the center of the inflammatory cascade. This shift has prompted development of next-generation therapies that target specific pathogenic B-cell populations rather than wiping out all B cells, which carries infection risk.
Migraine Medications Old and New
Triptans have been the gold standard for stopping a migraine attack since the early 1990s. They constrict blood vessels in the brain and block pain signals. Newer drug classes, the gepants (like rimegepant and ubrogepant) and ditans (like lasmiditan), were developed partly because triptans cannot be used by people with cardiovascular disease due to their blood-vessel-constricting effects. Gepants block a molecule called CGRP that plays a central role in migraine pain, while lasmiditan targets serotonin receptors without narrowing blood vessels.
The trade-off, though, is effectiveness. A large network meta-analysis found that most triptans outperformed the newer agents at achieving pain freedom within two hours. Compared to lasmiditan, rimegepant, and ubrogepant, triptans were roughly one and a half to three times more likely to leave a patient pain-free at the two-hour mark.10PubMed Central. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine For patients who can safely take triptans, they remain the stronger choice. The newer drugs fill an important gap for people who cannot, but calling them an upgrade over triptans oversells the evidence. A separate category of CGRP-blocking antibodies (like erenumab and fremanezumab) serves a different purpose: they are taken regularly to prevent migraines rather than to treat an attack in progress.
Neuropathic Pain and Gabapentinoids
Gabapentin and pregabalin, collectively known as gabapentinoids, are among the most widely prescribed drugs for nerve pain from conditions like diabetic neuropathy, shingles, and chemotherapy-induced nerve damage. Despite their names suggesting a relationship to GABA, their main action is binding to a specific subunit of calcium channels in the nervous system. When nerves are injured, the production of this subunit ramps up, which increases abnormal pain signaling. Gabapentinoids bind to that subunit and dampen the overexcited signals.11PubMed Central. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit
The evidence that this is their true target is unusually strong. Studies using genetically altered mice have shown that removing the specific subunit or mutating its binding site completely eliminates the pain-relieving effects of pregabalin, confirming that the drug cannot work without it.12PubMed Central. Mechanisms of the gabapentinoids and α 2 δ ‐1 calcium channel subunit in neuropathic pain This clarity of mechanism is rare in neurology, where many drugs were discovered through trial and error and their precise workings remain debated.
Stroke Treatment and the Time Window
Stroke treatment is defined by urgency. The standard clot-dissolving drug, alteplase (also called rtPA), works best when given intravenously within three hours of symptom onset, though a later study extended the safe window to four and a half hours.13PubMed Central. Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature Every minute of delay means more brain tissue is lost, which is why public health campaigns stress recognizing stroke symptoms fast.
Beyond clot busters, researchers have spent decades trying to find “neuroprotective” drugs that shield brain cells from the damage of oxygen deprivation during a stroke. The results have been largely disappointing: hundreds of compounds showed promise in animal models but failed in human trials. One recent example illustrates how complicated this is. The drug NA-1, designed to interrupt a toxic signaling pathway triggered by low oxygen, did not improve outcomes in the overall stroke population in its pivotal trial. But in patients who did not receive alteplase, NA-1 significantly increased the proportion with good neurological outcomes compared to placebo. The researchers think alteplase may actually break down NA-1 in the bloodstream before it can work, an unexpected drug-drug interaction.14Exploration of Neuroprotective Therapy. Neuroprotective agents in acute ischemic stroke It is a cautionary tale about how biological complexity can sabotage an otherwise sound idea.
Alzheimer’s Disease and Amyloid-Clearing Antibodies
Alzheimer’s has been one of the most frustrating frontiers for drug development. Most attempts to slow the disease by targeting amyloid-beta, the protein that accumulates in sticky plaques in Alzheimer’s brains, failed in clinical trials for years. That changed recently with monoclonal antibodies like lecanemab and donanemab, which bind to amyloid-beta and help the brain clear it through several routes: stimulating immune cells in the brain to engulf the plaques, activating complement (a part of the immune system), dissolving fibrillar deposits, and even drawing amyloid out of the brain and into the bloodstream.15PubMed Central. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
The clinical benefits, however, are modest: these antibodies slow cognitive decline by a measurable but small amount over 18 months, and they carry a real risk of brain swelling and microbleeds, especially in people with certain genetic profiles. Whether that level of benefit justifies widespread use remains hotly debated. The drugs also need to be given by intravenous infusion and require regular brain MRIs to monitor for side effects, making treatment logistically demanding.
Genetic Therapies and Antisense Oligonucleotides
Some of the most exciting recent advances in neurology have come not from traditional drugs but from therapies that directly modify gene activity. Antisense oligonucleotides (ASOs) are short, synthetic pieces of genetic material designed to bind to specific RNA molecules and either silence a toxic protein or boost production of a missing one. Nusinersen, the first ASO approved for a neurological disease, treats spinal muscular atrophy (SMA), a devastating condition in which motor neurons progressively die. Nusinersen does not just slow the disease; in symptomatic patients, it actually improves symptoms.16PubMed Central. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
ASOs are now being developed for amyotrophic lateral sclerosis (ALS), Huntington’s disease, and Alzheimer’s. The platform is flexible: by changing the sequence of the oligonucleotide, you can in theory target any gene, which makes it adaptable to conditions caused by different genetic defects. The main practical limitation is delivery. ASOs for SMA are injected into the spinal fluid via lumbar puncture, which needs to be repeated every few months. That is manageable for a severe childhood disease but harder to scale for conditions affecting millions of older adults.
Drug Tolerance and the Benzodiazepine Puzzle
Benzodiazepines like diazepam and lorazepam boost GABA signaling and are effective for anxiety, insomnia, and acute seizures. But with regular use, the brain adapts. Tolerance develops, meaning the same dose produces a weaker effect, and stopping the drug can provoke withdrawal symptoms. The mechanisms behind benzodiazepine tolerance are surprisingly complex and not fully understood. Research points to changes in GABA receptor subunit composition, shifts in glutamate receptor activity, altered levels of other neurotransmitters like serotonin and dopamine, and even changes in the brain’s own neurosteroid system. Different benzodiazepine effects (sedation, anti-anxiety, anticonvulsant) may develop tolerance through different pathways, or the pathway may depend on which GABA receptor subtypes are activated.17PubMed Central. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?
This complexity is why there is no simple fix for benzodiazepine tolerance or dependence. It also explains why some patients lose the anti-anxiety benefit but still experience sedation, or vice versa. The hope is that developing drugs that target specific GABA receptor subtypes could provide the therapeutic benefits without the tolerance spiral, though such drugs are still in early development.
Nanoparticles and the Future of Brain Drug Delivery
Lipid nanoparticles, the same basic technology that made mRNA COVID vaccines possible, are being adapted to deliver treatments to the brain. The main challenge is that current lipid nanoparticles tend to accumulate in the liver, not the brain. Most existing formulations barely cross the blood-brain barrier.18Advanced Drug Delivery Reviews. Lipid nanoparticle-mediated drug delivery to the brain But their high drug-loading capacity means that even modest brain uptake could deliver a meaningful dose.19PubMed Central. Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date
Recent work has found creative solutions. One research team incorporated a molecule that binds serotonin receptors into the lipid nanoparticle itself, essentially giving the nanoparticle a “ticket” to cross the barrier. After intravenous injection, this modified nanoparticle achieved over fifty times more mRNA delivery to brain tissue compared to the formulation used in the FDA-approved liver-targeting drug Onpattro.20PubMed Central. Lipid nanoparticles for mRNA delivery in brain via systemic administration That is still an early-stage animal result, but it suggests that engineering nanoparticles to interact with the barrier’s own biology, rather than trying to brute-force past it, may be the most productive path forward.
Why Age Changes How These Drugs Work
The same neurological medication can behave very differently in a twenty-five-year-old and a seventy-five-year-old. As the brain ages, it loses neurons, its neurotransmitter and receptor levels shift, and its ability to compensate for drug-induced changes diminishes. These changes make older adults more sensitive to neurological side effects from individual medications and from the cumulative burden of taking several drugs at once.21PubMed Central. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals Sedation, confusion, and falls from benzodiazepines, anticholinergic drugs, or even certain antihistamines are a major cause of hospitalization in older adults.
Antipsychotic medications illustrate the side-effect burden from another angle. These drugs, used for schizophrenia and sometimes for agitation in dementia, commonly produce extrapyramidal symptoms: muscle stiffness, tremor, and involuntary movements reminiscent of Parkinson’s disease. Research has found that patients who develop these symptoms early in treatment also tend to perform worse on cognitive tests, with lower scores on visual-motor tasks in particular.22PubMed Central. Extrapyramidal symptoms predict cognitive performance after first-episode psychosis In an older brain that is already vulnerable, these added insults compound quickly.
Pharmacogenomics and Why the Same Drug Works Differently in Different People
Genetic variation helps explain why one person does well on a seizure medication and another gets intolerable side effects at the same dose. Genes influence how quickly your body breaks down a drug (pharmacokinetics), how strongly your brain cells respond to it (pharmacodynamics), and even the underlying biology of the disease itself. In epilepsy, for example, researchers have identified genetic variants in drug-metabolizing enzymes and in the ion channels that antiseizure drugs target. But robust, clinically actionable findings remain scarce; many reported associations are still controversial or have not been replicated consistently.23PubMed Central. Pharmacogenomics in epilepsy
One clear success story is HLA-B*15:02 screening before prescribing carbamazepine. People carrying this genetic variant, most common in Southeast Asian populations, have a high risk of a severe, potentially fatal skin reaction to the drug. Screening before prescribing has become standard practice in many countries and has meaningfully reduced these reactions. Beyond that, pharmacogenomic testing in neurology is still more promise than routine practice, though it is slowly becoming incorporated into prescribing decisions for a handful of drugs.
Timing Doses to the Body Clock
The blood-brain barrier is not a static wall. Its permeability fluctuates with circadian rhythms, meaning the same drug taken in the morning may cross into the brain differently than the same dose taken at night.24PubMed Central. Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery Researchers are beginning to explore whether matching drug dosing to these daily rhythms, an approach called chronopharmacology, could improve how well neurological medications work while reducing side effects. Some seizure medications, for instance, are already dosed more heavily before the time of day when a patient’s seizures tend to cluster, but formalizing this with barrier-permeability data is a newer concept. The practical applications are still being worked out, but the principle is straightforward: the brain’s gatekeeper keeps different hours on different shifts, and timing your knock could matter.
Huntington’s Disease and the Search for Disease-Modifying Drugs
Huntington’s disease, caused by a single known genetic mutation, has proven stubbornly resistant to treatment. Current medications manage symptoms rather than slowing the disease. Tetrabenazine and its newer relative deutetrabenazine reduce chorea, the involuntary jerky movements that are a hallmark of Huntington’s, by depleting dopamine at nerve terminals. Riluzole, a glutamate-blocking drug already used in ALS, showed some promise in small studies: a randomized trial found that a higher dose reduced chorea scores compared to placebo, though a lower dose did not produce a meaningful difference.25PubMed Central. Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease Antisense oligonucleotides targeting the mutant huntingtin protein were a major source of hope, but a prominent trial was halted due to safety concerns, sending researchers back to refine the approach.